{"date":"2025-12-31","count":13,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7871-2025-12-31-1846-1jqigmd","company_id":"7871","company":"安立璽榮-KY","market":"興櫃","industry":"生技醫療","date":"2025-12-31","time":"18:46:38","subject":"代子公司Elixiron Immunotherapeutics (Hong Kong) limited公告研發免疫抗體新藥EI-001-二期臨床試驗治療非分節型白斑症，完成第一例受試者收案。","clause":"第9款","fact_date":"2025-12-30","cite_as":"公開資訊觀測站重大訊息：安立璽榮-KY（7871），2025-12-31 18:46，「代子公司Elixiron Immunotherapeutics (Hong Kong) limited公告研發免疫抗體新」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4728-2025-12-31-1713-dote83","company_id":"4728","company":"雙美","market":"上櫃","industry":"生技醫療","date":"2025-12-31","time":"17:13:39","subject":"公告本公司副總經理異動。","clause":"第8款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：雙美（4728），2025-12-31 17:13，「公告本公司副總經理異動。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6518-2025-12-31-1712-1bkm0mx","company_id":"6518","company":"康科特","market":"興櫃","industry":"生技醫療","date":"2025-12-31","time":"17:12:56","subject":"公告本公司代理發言人異動","clause":"第11款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：康科特（6518），2025-12-31 17:12，「公告本公司代理發言人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6518-2025-12-31-1712-l7qirp","company_id":"6518","company":"康科特","market":"興櫃","industry":"生技醫療","date":"2025-12-31","time":"17:12:21","subject":"公告本公司會計主管異動","clause":"第11款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：康科特（6518），2025-12-31 17:12，「公告本公司會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6891-2025-12-31-1653-1i9e80g","company_id":"6891","company":"樂迦再生","market":"興櫃","industry":"生技醫療","date":"2025-12-31","time":"16:53:30","subject":"公告本公司法人董事行政院國家發展基金管理會改派代表人","clause":"第6款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：樂迦再生（6891），2025-12-31 16:53，「公告本公司法人董事行政院國家發展基金管理會改派代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7871-2025-12-31-1633-18d0r72","company_id":"7871","company":"安立璽榮-KY","market":"興櫃","industry":"生技醫療","date":"2025-12-31","time":"16:33:09","subject":"公告本公司受邀參加元大證券舉辦之興櫃前法人說明會","clause":"第9款","fact_date":"2026-01-05","cite_as":"公開資訊觀測站重大訊息：安立璽榮-KY（7871），2025-12-31 16:33，「公告本公司受邀參加元大證券舉辦之興櫃前法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7725-2025-12-31-1622-p67uuk","company_id":"7725","company":"列特博","market":"興櫃","industry":"生技醫療","date":"2025-12-31","time":"16:22:21","subject":"公告本公司內部稽核主管異動","clause":"第11款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：列特博（7725），2025-12-31 16:22，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6814-2025-12-31-1616-1pzjlpi","company_id":"6814","company":"路迦生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-31","time":"16:16:44","subject":"公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形","clause":"第44款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：路迦生醫（6814），2025-12-31 16:16，「公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2025-12-31-1523-1dle2w8","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2025-12-31","time":"15:23:53","subject":"公告本公司辦理減資資本變更登記完成暨調整換股作業時程","clause":"第36款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2025-12-31 15:23，「公告本公司辦理減資資本變更登記完成暨調整換股作業時程」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4104-2025-12-31-1521-1vs1pz6","company_id":"4104","company":"佳醫","market":"上市","industry":"生技醫療","date":"2025-12-31","time":"15:21:21","subject":"公告本公司114年現金增資發行新股認股基準日等相關事宜(補充公告發行價格)","clause":"第11款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：佳醫（4104），2025-12-31 15:21，「公告本公司114年現金增資發行新股認股基準日等相關事宜(補充公告發行價格)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4117-2025-12-31-1512-1wsvuta","company_id":"4117","company":"普生","market":"興櫃","industry":"生技醫療","date":"2025-12-31","time":"15:12:31","subject":"公告本公司114年11月份自結合併財務報告之負債比率、流動比率及速動比率","clause":"第44款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：普生（4117），2025-12-31 15:12，「公告本公司114年11月份自結合併財務報告之負債比率、流動比率及速動比率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6499-2025-12-31-1434-1vxqdqq","company_id":"6499","company":"益安","market":"上櫃","industry":"生技醫療","date":"2025-12-31","time":"14:34:52","subject":"代重要子公司意能生技股份有限公司公告114年第三次普通股暨特別股股東臨時會重要決議事宜","clause":"第18款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：益安（6499），2025-12-31 14:34，「代重要子公司意能生技股份有限公司公告114年第三次普通股暨特別股股東臨時會重要決議事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4737-2025-12-31-0926-1qw9q1o","company_id":"4737","company":"華廣","market":"上市","industry":"生技醫療","date":"2025-12-31","time":"09:26:29","subject":"公告本公司訂定114年現金增資認股基準日等相關事宜（補充每股發行價格、代收及存儲價款專戶機構）","clause":"第11款","fact_date":"2025-12-31","cite_as":"公開資訊觀測站重大訊息：華廣（4737），2025-12-31 09:26，「公告本公司訂定114年現金增資認股基準日等相關事宜（補充每股發行價格、代收及存儲價款專戶機構）」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}